March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.